Lucentis Injection: How It Works, Results and What to Expect

A Lucentis injection is an anti-VEGF medicine injected into the gel-like fluid inside the eye to treat retinal diseases that cause leaking blood vessels or swelling. It is designed to protect vision and may improve vision in some people, although results depend on the underlying eye condition and how early treatment begins.

Lucentis Injection Overview

A Lucentis injection is a treatment in which ranibizumab is placed into the vitreous, the clear gel inside the eye. It blocks vascular endothelial growth factor (VEGF), a protein that can cause abnormal retinal blood vessels to grow or become leaky. By reducing this leakage, Lucentis can lessen retinal swelling and help preserve central vision.

Retina specialists may use Lucentis for wet age-related macular degeneration (wet AMD), diabetic macular edema, macular edema caused by retinal vein occlusion, diabetic retinopathy, and myopic choroidal neovascularization. These conditions affect the retina, the light-sensitive tissue at the back of the eye. Age-related macular degeneration is one of the most common reasons anti-VEGF injections are considered.

Lucentis is not a cure for the underlying retinal disease. Its purpose is to control abnormal blood vessel activity and swelling over time. Monitoring appointments remain important, even when vision seems stable, because retinal changes may occur before they are noticeable.

How Lucentis Works and Who May Be a Candidate

VEGF is part of the body’s normal system for blood vessel growth. In certain eye diseases, however, excess VEGF causes fragile new vessels to develop beneath or within the retina, or makes existing vessels leak fluid. Fluid, blood and swelling in the macula—the area responsible for detailed central sight—can blur or distort vision.

Ranibizumab is a laboratory-made antibody fragment that binds to VEGF. This reduces VEGF activity in the eye and can allow fluid to clear from the retina. Optical coherence tomography (OCT), a painless retinal scan, is commonly used to measure fluid and guide ongoing treatment decisions.

A person may be considered for Lucentis when examination and imaging show active leakage or swelling that is likely to respond to anti-VEGF therapy. The ophthalmologist will review the diagnosis, vision in each eye, previous treatments, general health, current medicines and any history of eye infection or inflammation. Treatment may need to be postponed if there is an active infection in or around the eye.

Other retinal problems may require a different approach, such as laser treatment, surgery or observation. Decisions are individualized and are usually made by a retina specialist after reviewing scans and discussing the likely benefits, limitations and follow-up plan.

What Happens During a Lucentis Eye Injection

Lucentis injections are usually outpatient procedures. Before treatment, the eye is examined and vision may be checked. Dilating drops may be used for assessment, which can temporarily blur vision afterward. The clinician confirms the eye being treated and cleans the skin around the eye and eyelids carefully.

Local anesthetic drops, gel or a small anesthetic injection numb the surface of the eye. An antiseptic solution is used to lower the risk of infection, and an eyelid holder may be placed to keep blinking from interfering. The medicine is then injected through the white part of the eye with a very fine needle. The injection itself takes only seconds.

Most people notice pressure or mild discomfort rather than sharp pain. Afterward, the eye pressure and vision may be checked. Patients are generally able to return home the same day, but should arrange assistance if dilation has made their vision temporarily blurred or glare-sensitive.

The treatment plan may begin with injections at regular intervals, followed by continued treatment according to retinal scans and disease activity. Some people receive injections at fixed intervals, while others follow a treat-and-extend or as-needed plan. The schedule should not be changed without consulting the treating ophthalmologist.

Recovery Timeline, Benefits and Possible Risks

For the first day or two, the eye may feel scratchy, watery or mildly irritated. A small red patch on the white of the eye can occur where the needle entered and may take several days to resolve. A few temporary floaters or air bubbles can also be seen. These effects are often mild and settle without treatment.

Vision may be briefly blurred on the day of the injection because of dilating drops, surface irritation or the procedure itself. Improvement from reduced retinal fluid may be noticed over days to weeks, but the timing varies. Some people experience clearer or less distorted vision, while for others the main benefit is preventing further decline.

The most important benefit of Lucentis is its ability to reduce vision loss from active VEGF-related retinal disease. Earlier treatment and reliable follow-up can improve the chance of maintaining useful vision. However, response is influenced by the diagnosis, how long the retina has been affected, scarring and other eye conditions.

Serious complications are uncommon but need prompt care. They include infection inside the eye (endophthalmitis), retinal detachment, significant bleeding, inflammation, lens injury and a rise in eye pressure. Anti-VEGF medicines may also have uncommon systemic risks, which the ophthalmologist considers in the context of a person’s cardiovascular and medical history.

Can Lucentis Restore Vision?

Lucentis can improve vision for some people, particularly when retinal swelling or leakage is treated before permanent damage develops. It may reduce distortion, improve reading vision or make central vision clearer as fluid resolves. The degree of improvement varies widely and cannot be predicted with certainty before treatment.

In many cases, preserving the vision that remains is the most realistic and valuable outcome. Lucentis cannot reverse retinal scarring or restore retinal cells that have been permanently damaged. Regular OCT monitoring helps the retina specialist determine whether the treatment is controlling disease activity and whether the plan should be adjusted.

People should continue using prescribed glasses, diabetes treatment, blood pressure management and other measures recommended for their eye condition. Lucentis works as one part of a broader plan for protecting eye health.

Which Is Better, Lucentis or Eylea?

Lucentis and Eylea are both anti-VEGF medicines used for several retinal diseases. Neither is automatically better for every person. They differ in their molecular design, approved uses in particular regions, treatment intervals, prior authorization requirements and how an individual retina responds.

For many conditions, both medicines have strong evidence for preserving vision when used appropriately. One person may respond well to Lucentis, while another may have better fluid control or a more convenient treatment interval with a different anti-VEGF medicine. The choice is guided by diagnosis, imaging results, treatment history, eye health and the specialist’s clinical judgment.

It is important not to delay or stop treatment while comparing options without medical guidance. If scans show persistent fluid or repeated recurrence, the retina specialist may discuss changing the injection schedule or medicine. A shared discussion can help clarify the expected benefits and practical follow-up needs of each option.

How Long After an Eye Injection Will Vision Improve?

Some people notice a change in vision within several days after a Lucentis injection, while others need several weeks or a series of injections before improvement is evident. The early goal is often to dry retinal fluid and stabilize vision rather than to produce an immediate noticeable change.

Vision can be temporarily blurred immediately after the procedure. This is usually related to dilating drops, the antiseptic preparation, surface irritation or temporary floaters. It is sensible to avoid driving until vision is clear enough to do so safely and to follow the clinic’s specific aftercare advice.

Retinal scans are more reliable than symptoms alone for judging treatment response. Even if vision feels unchanged, OCT may show reduced fluid; conversely, new fluid can develop before a person notices more blur. Keeping scheduled review appointments is therefore essential.

How Many Lucentis Injections Can You Have?

There is no single lifetime maximum number of Lucentis injections for all patients. Treatment can continue for months or years when there is evidence that it is benefiting the retina and the risks remain acceptable. The number depends on the condition being treated, how often fluid returns and the person’s response over time.

Some individuals need frequent injections at first, then longer gaps as the condition becomes controlled. Others continue to require ongoing injections because VEGF activity recurs when treatment is delayed. The retina specialist uses visual acuity, eye examination and OCT findings to decide whether another injection is needed.

Repeated injections are a well-established part of care for chronic retinal disease. Each procedure still carries a small risk, so the treatment plan should balance disease control with safety and the least burdensome effective schedule.

When to Seek Medical Care

Contact the eye clinic urgently after a Lucentis injection if there is increasing or severe eye pain, worsening redness, a marked drop in vision, increasing sensitivity to light, pus-like discharge, or rapidly increasing floaters. These symptoms can indicate a rare but serious complication and should not be managed by waiting for the next planned appointment.

Seek prompt assessment for new flashes of light, a curtain or shadow across vision, or sudden loss of peripheral vision. These can be warning signs of retinal detachment or another urgent retinal problem. Mild irritation, a small red patch or temporary floaters may occur after treatment, but patients should call their clinician if they are unsure whether a symptom is expected.

People with new distortion, blurred central vision, difficulty reading, dark spots or straight lines that appear wavy should arrange an eye examination, especially if symptoms begin suddenly. Early evaluation is important in conditions that can threaten central vision. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals provide retinal assessment and treatment for international patients.

Frequently asked questions

Is a Lucentis injection painful?

The eye is numbed before the injection, so most people feel pressure, a brief sensation or mild discomfort rather than significant pain. Scratchiness or irritation can occur afterward for a day or two. Severe or worsening pain is not expected and needs urgent assessment.

What should someone avoid after a Lucentis injection?

The treating clinic may advise avoiding rubbing or pressing on the treated eye and keeping water, makeup or unclean hands away from it for a short period. Driving should be avoided until vision is clear enough, particularly if dilating drops were used. Patients should follow the specific aftercare instructions given by their eye team.

Can Lucentis be used in both eyes?

Lucentis may be needed in both eyes when both have an eligible retinal condition. The timing and approach are decided by the retina specialist, taking account of infection-control practices and the person’s treatment needs. Each eye is assessed independently with examination and imaging.

How often are Lucentis injections given?

Frequency varies according to the retinal condition and treatment response. Injections may be given regularly at first and then continued at individualized intervals based on retinal scans and disease activity. Missing appointments can allow fluid or abnormal blood vessel activity to return.

Will I need eye drops after a Lucentis injection?

Many patients do not need routine antibiotic drops after an injection, although practices can differ by clinic and individual circumstances. Lubricating drops may sometimes help surface irritation if the eye team recommends them. Only use drops that have been approved by the treating clinician.

Can Lucentis injection cause cataracts?

Cataract formation is not a common direct effect of a properly performed intravitreal Lucentis injection. However, an uncommon complication such as accidental lens injury could contribute to cataract development. The specialist monitors the eye for complications during follow-up.

References

• American Academy of Ophthalmology
• National Eye Institute
• U.S. Food and Drug Administration
• Royal College of Ophthalmologists
• National Institute for Health and Care Excellence

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.